What is Complete Genomics?
Established in June 2005, Complete Genomics operates as a dedicated research and development hub. The company's focus on genomics suggests a deep involvement in areas such as DNA sequencing, genetic analysis, and related biotechnologies. Its sustained access to substantial capital, including its most recent strategic investment, points to a robust business model and promising technological advancements that attract significant investor confidence. The company's longevity and consistent funding indicate a stable presence and ongoing innovation within the competitive life sciences landscape.
How much funding has Complete Genomics raised?
Complete Genomics has raised a total of $197M across 7 funding rounds:
Series A
$6M
Series B
$12M
Series C
$26.5M
Debt
$14.5M
Series D
$45M
Series E
$39M
Stock Offering
$54M
Series A (2006): $6M with participation from OVP Venture Partners and Enterprise Partners Venture Capital
Series B (2007): $12M, investors not publicly disclosed
Series C (2008): $26.5M supported by Highland Crusader Offshore Partners L.P., Enterprise Partners VI L.P., Prospect Venture Partners III L.P., and OVP Venture Partners VI L.P.
Debt (2009): $14.5M, investors not publicly disclosed
Series D (2009): $45M backed by Prospect Venture Partners, OrbiMed, Highland Capital Partners, OVP Venture Partners, and Essex Woodlands Health Ventures
Series E (2010): $39M with participation from Prospect Venture Partners, OrbiMed, Highland Capital Partners, OVP Venture Partners, Sands Capital, and Essex Woodlands Health Ventures
Stock Issuance/Offering (2010): $54M, investors not publicly disclosed
Key Investors in Complete Genomics
Prospect Venture Partners
Prospect Venture Partners is a venture capital firm specializing in the life sciences sector, focusing on building innovative biomedical companies. They support ventures from seed to growth stages with capital exceeding $1 billion.
OrbiMed
OrbiMed Advisors LLC is an investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health. They support companies at various development stages.
Highland Capital Partners
Highland Capital Partners is a venture capital firm that invests in entrepreneurs and startups, with a history of successful exits and IPOs. They manage $7 billion in assets and emphasize long-term partnerships.
What's next for Complete Genomics?
The substantial enterprise-level capital infusion, culminating in the recent strategic investment, positions Complete Genomics for accelerated expansion and further innovation. This financing is likely to fuel advancements in its core genomic technologies, potentially enabling the company to scale its operations, enhance its research capabilities, and broaden its market reach. The ongoing backing from prominent investors suggests a strategic focus on long-term growth and the development of cutting-edge solutions within the rapidly evolving genomics and biotechnology sectors. Future developments may include strategic partnerships, new product launches, or expansion into new therapeutic or diagnostic areas.
See full Complete Genomics company page
